RxDoctor Payments Data

Jacklyn Karli

Adult Health · Watertown, SDNPI 1003203456

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.3% of the total across 175 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Abbott at 43.9% of the total.

$3,324in general payments, 2019–2025

Across 175 payments — averaging $18.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$491
  • Johnson & Johnson$324
  • Novartis$261
  • E.r. Squibb & Sons, L.L.C.$165
  • Philips North America LLC$90
  • plus $533 from 14 others

What the payments were for

  • Food & beverage$3,16895%
  • Education$1555%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few adult health providers in South Dakotato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$53,842
Medicare patients
396
Services billed
1,619

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban198$166,529
XareltoRivaroxaban89$85,932
Repatha SureclickEvolocumab64$36,435
EntrestoSacubitril/Valsartan30$25,211
Praluent PenAlirocumab45$21,391
FarxigaDapagliflozin Propanediol22$20,956
BrilintaTicagrelor19$14,444
Repatha SyringeEvolocumab14$7,897
Metoprolol Succinate329$4,551
Potassium Chloride109$3,472
Ranolazine ErRanolazine30$2,023
Amiodarone Hcl152$1,559
Ezetimibe45$1,380
Digoxin88$1,275
Isosorbide Mononitrate ErIsosorbide Mononitrate211$1,179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$324$85,93289 claims
AstraZenecaFarxiga, Brilinta$65$35,40041 claims
NovartisEntresto$261$25,21130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few adult health providers in South Dakotaon file to place this against a meaningful peer group, so we don't.

Other adult health in Watertown

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →